NCT05354557View on ClinicalTrials.gov

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

April 26, 2026

Study Completion Date

April 26, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Iberdomide

Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles

Trial Locations (8)

10021

Weill Cornell Medical College (Data Collection Only), New York

10065

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10604

Memorial Sloan Kettering Westchester (Consent and Follow Up), Harrison

11553

Memorial Sloan Kettering Nassau (Consent and Followup), Rockville Centre

11725

Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up), Commack

07920

Memorial Sloan Kettering Basking Ridge (Consent and Followup), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent and Follow-Up only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER